Brain Cancer | Specialty

The brain cancer condition center is a comprehensive resource for clinical news and expert insights on brain cancer. Read more at OncLive.

The OncFive: Top Oncology Articles for the Week of 9/7

September 13th 2025

The FDA has approved TAR-200 in urothelial cancer and selumetinib in pediatric NF-1–associated inoperable plexiform neurofibromas, and more.

FDA Approves Selumetinib for Symptomatic Pediatric NF-1–Associated Inoperable Plexiform Neurofibromas

September 10th 2025

The FDA approved selumetinib granules and capsules for the treatment of pediatric patients at least 1 year of age with NF1 and plexiform neurofibromas.

Dr Monje on the Role of a Novel GD2-Directed CAR T-Cell Therapy in Diffuse Midline Glioma

September 9th 2025

Michelle Monje, MD, PhD, discusses the early efficacy of a novel GD2-directed CAR T-cell therapy for the treatment of children with diffuse midline glioma.

NCCN Adds Dordaviprone to Clinical Practice Guidelines in H3K27M-Mutant Diffuse High-Grade Glioma

September 9th 2025

Dordaviprone was included as a category 2A single agent in the NCCN guidelines for recurrent or progressive H3K27M-mutant diffuse high-grade glioma.

New Genetic Biomarker Flags Aggressive Brain Tumors

September 8th 2025

A new study suggests that if a tumor shows activity in the TERT gene, it tends to recur more quickly, even if it looks low-grade under the microscope.

The OncFive: Top Oncology Articles for the Week of 8/31

September 6th 2025

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

GD2-Directed CAR T-Cell Therapy Generates Early Antitumor Activity in H3K27M-Mutant Diffuse Midline Glioma

September 3rd 2025

Michelle Monje, MD, PhD, highlights early efficacy data with a GD2-directed CAR T-cell therapy for H3K27M-mutant diffuse midline gliomas.

OncLive’s August Roundup of Key FDA Approvals in Oncology: 3 Decisions to Know

September 2nd 2025

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

Five Under 5: Top Oncology Videos for the Week of 8/3

August 10th 2025

The top 5 OncLive videos of the week cover insights in renal cell carcinoma, glioma, multiple myeloma, and ovarian cancer.

The OncFive: Top Oncology Articles for the Week of 8/3

August 9th 2025

The FDA grants accelerated approval to zongertinib in lung cancer, clears dordaviprone in glioma, and awards priority review to liso-cel sBLA in MZL.

FDA Approves Dordaviprone for Diffuse Midline Glioma

August 6th 2025

The FDA granted accelerated approval to dordaviprone for patients at least 1 year of age with progressive H3K27M-mutated diffuse midline glioma.

Dr Blanco on the Conditional EU Approval of Mirdametinib for NF1-Associated PNs

July 31st 2025

Ignacio Blanco, MD, PhD, discusses the significance of the European approval of mirdametinib for symptomatic, inoperable plexiform neurofibromas.

CHMP Recommends EU Approval of Vorasidenib for IDH1/2-Mutant Grade 2 Glioma

July 25th 2025

The CHMP has issued a positive opinion for the use of vorasidenib in IDH1/IDH2-mutant grade 2 glioma

EU Grants Conditional Approval of Mirdametinib for NF1-Associated Plexiform Neurofibromas

July 21st 2025

Mirdametinib received conditional EU approval for treating NF1-associated plexiform neurofibromas in patients 2 years of age and older.

FDA Grants Orphan Drug Designation to SH-110 for Oral Suspension in Glioma

July 16th 2025

SH-110 received orphan drug designation from the FDA for the treatment of patients with glioma.

MB-101 Receives FDA Orphan Drug Designation for Astrocytoma and Glioblastoma

July 8th 2025

The FDA granted orphan drug designation to MB-101 for recurrent diffuse and anaplastic astrocytoma and glioblastoma.

Early Data Show 3-Year Survival Benefit, Potential Temferon-Mediated Disease Control in Glioblastoma Multiforme

July 1st 2025

Long-term survival signals with Temferon in 2 patients with newly diagnosed glioblastoma multiforme suggest potential mediation of disease progression.

The OncFive: Top Oncology Articles for the Week of 6/22

June 28th 2025

The FDA grants approval to Dato-DXd in EGFR+ NSCLC, revumenib sNDA is under priority review for NPM1-mutant AML, and more from OncLive this week.

FDA Grants Fast Track Designation to RAD101 for Imaging of Brain Metastases

June 12th 2025

The FDA granted fast track designation to RAD101 for imaging of cerebral metastases from various solid tumors, including leptomeningeal metastases.

Iopofosine I-131 Demonstrates Safety and Early Efficacy in Pediatric R/R High-Grade Glioma

June 11th 2025

Data from the phase 1 CLOVER-2 trial demonstrated the safety and activity of iopofosine I-131 in relapsed/refractory pediatric high-grade glioma.